Martin Wythes
Pfizer (United States)(US)
Publications by Year
Research Areas
Cancer-related gene regulation, Chemical Synthesis and Analysis, Asymmetric Synthesis and Catalysis, Tryptophan and brain disorders, Synthesis and Catalytic Reactions
Most-Cited Works
- → Preparation of enantiomerically pure protected 4-oxo .alpha.-amino acids and 3-aryl .alpha.-amino acids from serine(1992)190 cited
- → Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate(2017)135 cited
- → Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)(2017)126 cited
- → Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy(2018)83 cited
- → Design of Selective, ATP-Competitive Inhibitors of Akt(2010)75 cited
- → A new direct method for the synthesis of enantiomerically pure protected α-amino acids(1989)71 cited
- → UK-69, 578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic(1989)68 cited
- → Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 H )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors(2016)68 cited
- → A New Approach to the Synthesis of .beta.-Hydroxy-.alpha.-amino Acids Using (Arylthio)nitrooxiranes(1995)62 cited
- → Synthesis of enantiomerically pure protected β-aryl alanines(1989)57 cited